Quote:
The 10k was outstandingly clear. OWC is an IP (Intellectual Property) research company in the pre-clinical stages for treatment of psoriasis and multiple myeloma . They also have plans to begin studies on other skin conditions , fibromyalgia and PTSD . **Do an internet search for those medical conditions to research the market potential.**

Attention to detail matters...

OWC never claimed their research would start generating revenue in Q2-2017 . In their annual report in January they stated by Q2 the cream would be "market ready" and they would "initiate marketing program" which has to happen before generating revenue.

OWC never claimed to have been approved for or started any clinical studies using their sublingual tablet.
"The Company’s longer-term objectives include the commencement of clinical trials using its proprietary sublingual tablet as the basis for cannabinoid-based drug trials."
**From 1-17-17 [8k]: https://www.otcmarkets.com/edgar/GetFilingHtm...11784384**

The 10K is not meant to be sunshine and rainbows. It is meant to give an unbiased view of the enterprise from a business perspective. It covers them from liability and people who would take them to court for no other reason than not being totally upfront about the inherent risk associated with investing in pennystock companies. Especially in OWC's case since we are dealing with a pre-revenue, pre-clinical, *cannabis-based*, OTC stock with an International subsidiary. Pennystocks are risky, but so is driving on the highway.